The Association for Clinical Oncology (ASCO) congratulates Dr. Francis Collins on his long and impactful tenure as Director of the National Institutes of Health (NIH).
October 5, 2021
August 6, 2021
The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer.
May 25, 2021
The Association for Clinical Oncology (ASCO) congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Brooks-LaSure is now in a key position to lead CMS during the agency’s continued response to the COVID-19 pandemic and the evolving implementation of the Affordable Care Act (ACA) under the new Administration.
April 14, 2021
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Jasmine Kamboj, MD, for her exceptional contributions to advocacy efforts to improve cancer care and research. A current member of ASCO’s Health Equity Committee, Dr. Kamboj volunteered much of her time to advocate on behalf of cancer advocacy priorities that impact people with cancer and their cancer care teams.
April 14, 2021
The Association for Clinical Oncology (ASCO) presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
April 9, 2021
The Association for Clinical Oncology (ASCO) applauds the proposed $9 billion funding increase for the National Institutes of Health (NIH) in President Biden’s budget request for Fiscal Year (FY) 2022. Such a significant proposed investment in biomedical research demonstrates a real commitment from the Administration to supporting the nation’s research infrastructure.
March 19, 2021
The Association for Clinical Oncology (ASCO) congratulates Xavier Becerra on his confirmation as Secretary of the Department of Health and Human Services (HHS). Secretary Becerra is now in a key position to lead HHS during the agency’s continued response to the COVID-19 pandemic and to address the many challenges facing patients and providers across the cancer care delivery system, such as health care disparities and the high cost of care.
February 23, 2021
The Association of Clinical Oncology congratulates the eleven practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020.
January 26, 2021
ALEXANDRIA, Va. – Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and white Americans have been selected to participate in the American Society of Clinical Oncology’s (ASCO) quality programs, including the Quality Oncology Practice Initiative (QOPI®) and Quality Training Program (QTP). Today ASCO and Susan G. Komen (Komen), with funding from the Fund II Foundation for each practice’s training and participation, announced the recipients. The three-year program, will be administered through Conquer Cancer, the ASCO Foundation.
January 19, 2021
On the eve of his inauguration, the Association for Clinical Oncology (ASCO) congratulates Joseph R. Biden, Jr., the 46th President of the United States.
December 23, 2020
The Association for Clinical Oncology (ASCO) applauds the decision by the U.S. District Court for the District of Maryland to grant a temporary restraining order on the implementation of the Most Favored Nation (MFN) Interim Final Rule. Judge Blake’s decision delays the model’s implementation for 14 days while she considers a preliminary injunction, which would further delay the model. The decision notes that there is likely to be irreparable harm if the rule goes into effect January 1, suggesting that the preliminary injunction will likely be granted.
December 22, 2020
Congress took a giant step forward to reduce health disparities by expanding clinical trial access to more than 41.6 million Medicaid beneficiaries through passage of the bipartisan CLINICAL TREATMENT Act as part of its end-of-year legislative package. We commend Congress for passing this commonsense fix to increase the diversity of participants in clinical trials, improve the validity of clinical research, and help reduce disparities in treatment outcomes for people with life-threatening diseases—disparities that have only been magnified by the COVID-19 pandemic.
December 17, 2020
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
November 24, 2020
The Association for Clinical Oncology (ASCO) opposes the Most Favored Nation (MFN) Model for Medicare Part B drug reimbursement, which outlines a structured, nationwide, mandatory demonstration that will be phased in over four years, with full implementation for the final three years of the seven-year model. This plan effectively overrides a statutory provision under the guise of a demonstration project by imposing a new reimbursement model on cancer care absent any evidence that it can lower costs without negative consequences for Medicare beneficiaries.
September 30, 2020
ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
Pages |